With the advent of fully human MAbs, the efficacy and safety have improved in the treatment of various cardiovascular, cancer, respiratory, hematology, autoimmune diseases and infections. The introduction of biosimilars will increase the affordability and utilization of MAbs in the treatment of various diseases.
No takes yet. Share an insight, caveat, or question.
Singh et al. (2017) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: